Premium
Helicobacter pylori infection treated with a tripotassium dicitrato bismuthate and metronidazole combination
Author(s) -
WEIL J.,
BELL G. D.,
POWELL K.,
MORDEN A.,
HARRISON G.,
GANT P. W.,
JONES P. H.,
TROWELL J. E.
Publication year - 1990
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.1990.tb00513.x
Subject(s) - metronidazole , medicine , helicobacter pylori , gastroenterology , urea breath test , breath test , antibiotics , microbiology and biotechnology , helicobacter pylori infection , biology
SUMMARY Seventy‐two patients with H. pylori infection in their antral mucosa took part in the study. Forty‐three received metronidazole 400 mg t.d.s. for two weeks, plus De‐Nol tabs 2 b.d. for four weeks, and the remaining 29 patients received metronidazole 400 mg t.d.s. for two weeks plus De‐Nol liquid 5 ml q.d.s. for four weeks. Seven of 57 H. pylori isolates were found to have pre‐treatment metronidazole resistance. Success, in terms of eradication of H. pylori , was assessed using a one‐month post‐treatment 14 C urea breath test. Successful eradication of H. pylori was achieved in 72% and 79%, respectively, of the metronidazole/De‐Nol tablet and metronidazole/De‐Nol liquid groups. These figures increased to 87% and 84%, respectively, if the patients whose organisms were known to be metronidazole‐sensitive were considered in isolation. H. pylori was successfully eradicated in only one of seven patients with a metronidazole‐resistant organism.